2022 ASCO GI Annual Meeting

January 12, 2023

Haystack is looking forward to attending the ASCO Gastrointestinal Cancers Annual Symposium taking place January 19-21 in San Francisco, CA. ASCO GI will be celebrating 20 years of offering the latest innovative science, solution-focused strategies, and multidisciplinary approaches in GI cancer treatment, research, and care. If you’re there, please stop by table #43 and learn about Haystack’s MRD test that delivers unmatched ctDNA detection sensitivity and accuracy for superior post-surgical treatment management.

Subscribe for updates

No spam, notifications only about new products, updates.

News and events

Haystack MRD™ by Quest Diagnostics^® at SSO 2025

March 18, 2025

We invite you to connect with us at SSO 2025 to learn how Haystack MRD can help guide treatment decisions with confidence. From the perioperative setting to recurrence surveillance, Haystack MRD tracks ctDNA across the treatment management journey—empowering oncologists to

Two leading oncologists take a deep dive into how groundbreaking advancements are providing a clearer crystal ball for guiding patient care

January 21, 2025

Oncologists like Dr Doug Flora and Dr Debra Patt are realists. But when they began to use new tools to find cancer that surgery or treatment might have missed, something exciting happened. “The key is, MRD (minimal residual disease testing)

More news and events

Follow us on social media

Purpose-built, high-precision MRD testing

Connect with us

Your Privacy Choices

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.